FDX1 and cervical squamous cell carcinoma: While in bladder urothelial carcinoma (BLCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), esophageal carcinoma (ESCA), liver hepatocellular carcinoma (LIHC), and sarcoma (SARC), FDX1 showed no significant expression difference compared to normal tissues.